Goldman Sachs’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $825K | Buy |
32,186
+12,714
| +65% | +$326K | ﹤0.01% | 3957 |
|
|
2025
Q1 | $535K | Buy |
19,472
+2,047
| +12% | +$56.3K | ﹤0.01% | 4218 |
|
|
2024
Q4 | $470K | Sell |
17,425
-30,417
| -64% | -$820K | ﹤0.01% | 4330 |
|
|
2024
Q3 | $1.38M | Sell |
47,842
-18,655
| -28% | -$538K | ﹤0.01% | 3582 |
|
|
2024
Q2 | $1.81M | Buy |
66,497
+21,933
| +49% | +$598K | ﹤0.01% | 3253 |
|
|
2024
Q1 | $1.25M | Sell |
44,564
-17,628
| -28% | -$494K | ﹤0.01% | 3487 |
|
|
2023
Q4 | $1.66M | Buy |
62,192
+26,703
| +75% | +$711K | ﹤0.01% | 3324 |
|
|
2023
Q3 | $907K | Buy |
35,489
+27,239
| +330% | +$696K | ﹤0.01% | 3586 |
|
|
2023
Q2 | $216K | Buy |
+8,250
| New | +$216K | ﹤0.01% | 4365 |
|
|
2023
Q1 | – | Sell |
-20,039
| Closed | -$550K | – | 5161 |
|
|
2022
Q4 | $550K | Hold |
20,039
| – | – | ﹤0.01% | 4044 |
|
|
2022
Q3 | $482K | Hold |
20,039
| – | – | ﹤0.01% | 4272 |
|
|
2022
Q2 | $530K | Hold |
20,039
| – | – | ﹤0.01% | 4340 |
|
|
2022
Q1 | $533K | Hold |
20,039
| – | – | ﹤0.01% | 4533 |
|
|
2021
Q4 | $542K | Hold |
20,039
| – | – | ﹤0.01% | 4458 |
|
|
2021
Q3 | $517K | Hold |
20,039
| – | – | ﹤0.01% | 4364 |
|
|
2021
Q2 | $519K | Hold |
20,039
| – | – | ﹤0.01% | 4408 |
|
|
2021
Q1 | $512K | Buy |
+20,039
| New | +$512K | ﹤0.01% | 4338 |
|